Strug­gling CTI gets a mixed bag of PhI­II re­sults for a lead drug still un­der a full hold at the FDA

With its stock firm­ly plant­ed in pen­ny ter­ri­to­ry, the strug­gling CTI Bio­Phar­ma $CTIC re­vealed that its top as­set pa­cri­tinib achieved mixed re­sults in a Phase III study, hit­ting one end­point and miss­ing an­oth­er ac­cord­ing to pre­lim­i­nary num­bers. The drug, though, was put on a full clin­i­cal hold back in Feb­ru­ary, af­ter the FDA took a look at new da­ta in­di­cat­ing that pa­tients in the drug arm were dy­ing faster than sub­jects in the con­trol arm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.